Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
Biochimica Et Biophysica Acta. General Subjects|January 25, 2022
Engineering tumor stromal mechanics for improved T cell therapyLinxuan Ying, Mahsa Yazdani, Richard Koya, et al.Wound Repair and Regeneration : Official Publication of the Wound Healing Society [And] the European Tissue Repair Society|June 12, 2021
Engineered microenvironment for the study of myofibroblast mechanobiologyYing Xu, Richard Koya, Kjetil Ask, et al.Oncoimmunology|May 10, 2019
Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancerMuzamil Yaqub Want, Anna Konstorum, Ruea-Yea Huang, et al.Cancer Immunology, Immunotherapy : CII|April 23, 2022
Tcf-1 protects anti-tumor TCR-engineered CD8+ T-cells from GzmB mediated self-destructionBrendan Zangari, Takemasa Tsuji, Junko Matsuzaki, et al.Pharmaceutics|September 23, 2022
pH Sensitive Erythrocyte-Derived Membrane for Acute Systemic Retention and Increased Infectivity of Coated Oncolytic Vaccinia VirusKaelan T Samoranos, Alexandra L Krisiewicz, Bianca C Karpinecz, et al.Journal for Immunotherapy of Cancer|October 5, 2021
CXCR6 by increasing retention of memory CD8+ T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancerRavikumar Muthuswamy, Aj Robert McGray, Sebastiano Battaglia, et al.Journal for Immunotherapy of Cancer|March 25, 2025
mTOR inhibition modulates vaccine-induced immune responses to generate memory T cells in patients with solid tumorsHenry G Withers, Junko Matsuzaki, Mark Long, et al.Journal of Immunology (Baltimore, Md. : 1950)|July 9, 2008
CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma modelArvind Chhabra, Lili Yang, Pin Wang, et al.Journal of Translational Medicine|November 7, 2012
A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapiesAdrian Bot, Mark Ahn, Marnix Bosch, et al.Science Translational Medicine|March 16, 2022
Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responsesKunle Odunsi, Feng Qian, Amit A Lugade, et al.Pageof 1